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I) DESCRIPTION OF COHORTS 
 
Age, Gene/Environment Susceptibility – Reykjavik Study (AGES): The Reykjavik Study cohort 
originally was composed of a random sample of 30,795 men and women born in 1907-1935 and 
living in Reykjavik in 1967.1 A total of 19,381 attended, resulting in 71% recruitment rate. The 
study sample was divided into six groups by birth year and birth date within month. One group 
was designated for longitudinal follow-up and was examined in all stages. Another group was 
designated a control group and was not included in examinations until 1991. Other groups were 
invited to participate in specific stages of the study. Between 2002 and 2006, the AGES-
Reykjavik study re-examined 5,764 survivors of the original cohort who had participated before 
in the Reykjavik Study. 
 
Atherosclerosis Risk in Communities (ARIC) Study: The ARIC study is an ongoing population-
based cohort of 15,792 predominantly Caucasian and African-American males and females 
aged 45-64 years at baseline and selected using probability sampling from four United States 
communities (Forsyth County NC, Jackson MS, suburban Minneapolis MN, and Washington 
County MD).2 Participants were recruited in 1987-1989 to examine cardiovascular and 
pulmonary disease, patterns of medical care, and disease variation over time. Standardized 
physical examinations and interviewer-administered questionnaires were conducted at baseline 
(1987-1989), and at three triennial follow-up examinations (1990-1998). 
 
Cardiovascular Health Study (CHS):  The CHS is a population-based cohort study of risk factors 
for CHD and stroke in adults ≥65 years conducted across four field centers.3 The original 
predominantly Caucasian cohort of 5,201 persons was recruited in 1989-1990 from random 
samples of the Medicare eligibility lists; subsequently, an additional predominantly African-
American cohort of 687 persons was enrolled for a total sample of 5,888. DNA was extracted 
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from blood samples drawn on all participants at their baseline examination in 1989-90. In 2007-
2008, genotyping was performed at the General Clinical Research Center's 
Phenotyping/Genotyping Laboratory at Cedars-Sinai using the Illumina 370CNV BeadChip 
system on 3,980 CHS participants who were free of CVD at baseline, consented to genetic 
testing, and had DNA available for genotyping. 
 
Health, Aging, and Body Composition Study (Health ABC): The Health ABC Study is a NIA-
sponsored cohort study of the factors that contribute to incident disability and the decline in 
function of healthy older persons, with a particular emphasis on changes in body composition in 
old age. Between 4/15/97 and 6/5/98 the Health ABC study has recruited 3,075 70-79 year old 
community-dwelling adults (41% African-American), who were initially free of mobility and 
activities of daily living disability. The key components of Health ABC include a baseline exam, 
annual follow-up clinical exams, and phone contacts every 6 months to identify major health 
events and document functional status between clinic visits. Provision has been made for 
banking of blood specimens and extracted DNA (Health ABC repository). 
 
Hispanic Community Health Study / Study of Latinos (HCHS/SOL): The Hispanic Community 
Health Study/Study of Latinos (HCHS/SOL) is a community based cohort study of 16,415 self-
identified Hispanic/Latino persons aged 18-74 years from randomly selected households in four 
U.S. field centers (Chicago, IL; Miami, FL; Bronx, NY; San Diego, CA) with baseline 
examination (2008 to 2011) and yearly telephone follow-up assessment for at least three years.4 
The two-stage sampling design selected households within census block groups. Households 
with Hispanic/Latino surnames and individuals over 45 years of age were oversampled to 
achieve increased representation of Hispanic/Latino individuals with a uniform age distribution. 
Due to this study design, sampling weights that reflect the probability of sampling individuals to 
the study were calculated for all individuals. These sampling weights were used in downstream 
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analyses to protect against potential selection bias arising from the sampling scheme. The 
HCHS/SOL cohort includes participants who self-identified as having Hispanic/Latino 
background, the largest groups being Central American, Cuban, Dominican, Mexican, Puerto-
Rican, and South American. The HCHS/SOL study was approved by institutional review boards 
at participating institutions, and written informed consent was obtained from all participants. 
12,803 individuals were successfully genotyped on an Illumina Omni 2.5M array, and the 
genotype and phenotype data are posted on dbGaP (accession numbers phs000880.v1.p1 and 
phs000810.v1.p1). 
 
Jackson Heart Study (JHS): The JHS is a single-site, prospective, population-based study 
designed to explore the environmental, behavioral, and genetic factors that influence the 
development of cardiovascular disease (CVD) among African Americans. A total of 5,301 
women and men between the ages of 21 and 94 were recruited between September 2000 and 
May 2004 from a tri-county area of Mississippi: Hinds, Madison, and Rankin Counties. 
Participants were recruited from four sources, including (1) randomly sampled households from 
a commercial listing; (2) ARIC study participants; (3) a structured volunteer sample that was 
designed to mirror the eligible population; and (4) a nested family cohort. Of the enrolled 
participants, 3,630 were recruited uniquely to JHS and did not participate in ARIC. Overviews of 
the JHS including the sampling and recruitment, sociocultural, and laboratory methods have 
been described previously.5 All of the participants provided written informed consent. 
Participants were between 35 and 84 years old at first visit, and members of the family cohort 
were ≥ 21 years old when consent for genetic testing was obtained and blood was drawn for 
DNA extraction. The details of first clinic visit procedures, including supine 12-lead digital 
electrocardiography (ECG), venipuncture, and other testing, have been previously described.  
The definitions of co-morbidities as well as the details of ECG measurements and medication 
collection and coding have also been reported.6, 7 
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Multi-Ethnic Study of Atherosclerosis (MESA): MESA is a study of the characteristics of 
subclinical cardiovascular disease (disease detected non-invasively before it has produced 
clinical signs and symptoms) and the risk factors that predict progression to clinically overt 
cardiovascular disease or progression of the subclinical disease. MESA researchers study a 
diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. 38 
percent of the recruited participants are white, 28 percent African-American, 22 percent 
Hispanic, and 12 percent Asian, predominantly of Chinese descent.8  Participants were recruited 
from six field centers across the United States. Two physical examinations (at baseline-1st and 
at 5th time points) were conducted since the electrocardiography was taken only at baseline 
and at 5th time points.  The tenets of the Declaration of Helsinki were followed and institutional 
review board approval was granted at all MESA sites. Written informed consent was obtained 
from each participant. 
 
The Netherlands Epidemiology of Obesity (NEO) study: The NEO study was designed for 
extensive phenotyping to investigate pathways that lead to obesity-related diseases. The NEO 
study is a population-based, prospective cohort study that includes 6,671 individuals aged 45–
65 years, with an oversampling of individuals with overweight or obesity. At baseline, 
information on demography, lifestyle, and medical history have been collected by 
questionnaires. In addition, samples of 24-h urine, fasting and postprandial blood plasma and 
serum, and DNA were collected. Genotyping was performed using the Illumina 
HumanCoreExome chip, which was subsequently imputed to the 1000 genome reference panel. 
Participants underwent an extensive physical examination, including anthropometry, 
electrocardiography, spirometry, and measurement of the carotid artery intima-media thickness 
by ultrasonography. In random subsamples of participants, magnetic resonance imaging of 
abdominal fat, pulse wave velocity of the aorta, heart, and brain, magnetic resonance 
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spectroscopy of the liver, indirect calorimetry, dual energy X-ray absorptiometry, or 
accelerometry measurements were performed. The collection of data started in September 
2008 and completed at the end of September 2012. Participants are currently being followed for 
the incidence of obesity-related diseases and mortality.  
 
Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): A detailed description of 
the PROSPER study has been published elsewhere.9, 10 PROSPER was a prospective 
multicenter randomized placebo-controlled trial to assess whether treatment with pravastatin 
diminishes the risk of major vascular events in elderly. Between December 1997 and May 1999, 
we screened and enrolled subjects in Scotland (Glasgow), Ireland (Cork), and the Netherlands 
(Leiden). Men and women aged 70-82 years were recruited if they had pre-existing vascular 
disease or increased risk of such disease because of smoking, hypertension, or diabetes. A 
total number of 5,804 subjects were randomly assigned to pravastatin or placebo. A large 
number of prospective tests were performed including Biobank tests and cognitive function 
measurements.  
 
Rotterdam Study (RS): The RS is a prospective population based cohort study comprising 7,983 
participants aged 55 years or older (RS1), which started in 1990. In 2000-2001, an additional 
3,011 individuals aged 55 years or older were recruited (RS2).11 At baseline, participants were 
interviewed at home and were examined at the research center, which included a 10 second, 
12-lead electrocardiogram (ECG). Since then, participants are followed continuously and re-
examined during several follow-up examination rounds. Medical information is available of all 
participants by collaboration with the general practitioners and with the pharmacies in the area 
of Ommoord. The Rotterdam Study has been approved by the medical ethics committee 
according to the “Wet Bevolkingsonderzoek: ERGO” (Population Study Act Rotterdam Study), 
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executed by the Ministry of Health, Welfare and Sports of the Netherlands and written informed 
consent was obtained from all study participants. 
 
Women’s Health Initiative Clinical Trials (WHI CT):  The WHI is a long-term national health 
study focused on strategies for preventing heart disease, breast and colorectal cancer, and 
osteoporotic fractures in postmenopausal women.  Between 1993 and 1998, it randomized 
68,132 women aged 50-79 years into one or more clinical trials of hormone therapy, dietary 
modification, or calcium/vitamin D supplementation.12 In this context, white WHI CT women 
were controls drawn from the Genome-wide Association Research Network into Effects of 
Treatment (GARNET),13 controls drawn from the Modification of PM-Mediated 
Arrhythmogenesis in Populations (MOPMAP),14 or participants in the Women's Health Initiative 
Memory Study (WHIMS).15 Black and Hispanic WHI CT women were participants in the single 
nucleotide polymorphism (SNP) Health Association Resource project (SHARe).16 
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II) TABLES AND FIGURES 
 
Supplemental Table 1. List of sulfonylurea drugs 
 
First-generation sulfonylureas 
Acetohexamide 
Chlorpropamide 
Tolazamide 
Tolbutamide 
 
Second-generation sulfonylureas 
Glimepiride 
Gliclazide 
Glipizide 
Glyburide 
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Supplemental Table 2. Medication assessment and electrocardiogram (ECG) measurement methods for each cohort 
 
Cohort 
Maximum 
Number 
of Visits 
Medication 
Assessment 
Time Period for 
Medication Assessment ECG Machine 
ECG Measurement 
System 
AGES ≤ 2 Medication Inventory At time of visit Marquette MAC 5000  Marquette 12SL 
ARIC 4 Medication Inventory 2 weeks before visit Marquette MAC PC Marquette 12SL 
CHS 10 Medication Inventory 2 weeks before visit Marquette MAC PC Marquette 12SL 
Health ABC 1 Medication Inventory 2 weeks before visit Marquette MAC PC Marquette 12SL 
HCHS/SOL 1 Medication Inventory 4 weeks before visit Marquette MAC 1200 Marquette 12SL 
JHS 1 Medication Inventory At time of visit Marquette MAC PC MEANS17, 18 
MESA 2 Medication Inventory 2 weeks before visit Marquette MAC 1200 Marquette 12SL 
NEO 1 Medication Inventory At time of visit Burdick Eclips 850i University of Glasgow 
PROSPER 1 Medication Inventory At time of visit Burdick Eclips 850i University of Glasgow 
Rotterdam 1 5 Pharmacy database 30 days before visit ACTA MEANS17, 18 
Rotterdam 2 3 Pharmacy database 30 days before visit ACTA MEANS17, 18 
WHI GARNET 4 Medication Inventory 2 weeks before visit Marquette MAC PC Marquette 12SL 
WHI MOPMAP 4 Medication Inventory 2 weeks before visit Marquette MAC PC Marquette 12SL 
WHI SHARe 4 Medication Inventory 2 weeks before visit Marquette MAC PC Marquette 12SL 
WHIMS 4 Medication Inventory 2 weeks before visit Marquette MAC PC Marquette 12SL 
 
Study abbreviations: AGES = Age, Gene/Environment Susceptibility – Reykjavik Study, ARIC = Atherosclerosis Risk in Communities Study, CHS 
= Cardiovascular Health Study, Health ABC = Health, Aging, and Body Composition Study, HCHS/SOL = Hispanic Community Health Study/Study 
of Latinos, JHS = Jackson Heart Study, MESA = Multi-Ethnic Study of Atherosclerosis, NEO = Netherlands Epidemiology of Obesity, PROSPER = 
Prospective Study of Pravastatin in the Elderly at Risk, Rotterdam 1 = first cohort of the Rotterdam Study, Rotterdam 2 = second cohort of the 
Rotterdam study, WHI GARNET = Women’s Health Initiative Genome-wide Association Research Network into Effects of Treatment, WHI 
MOPMAP = Women’s Health Initiative Modification of Particulate Matter-Mediated Arrhythmogenesis in Populations, WHI SHARe = Women’s 
Health Initiative SNP Health Association Resource, WHIMS = Women’s Health Initiative Memory Study. 
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Supplemental Table 3. Genotyping characteristics for each cohort 
 
Cohort 
Genotyping 
array 
Genotype 
calling 
Sample 
call rate 
filter 
SNP 
call rate 
filter 
SNP 
MAF 
filter 
HWE 
p-value 
filter 
Imputation 
software 
Imputation 
platform 
SNPs 
passing 
QC, N 
AGES Ilumina 370CNV BeadStudio >95% >97% <1% <10-6 MACH v1.0.16 HapMap2 308,340 
ARIC (EA) Affymetrix 6.0 Birdseed >95% >90% <1% <10-6 MACH v1.0.16 HapMap2 669,450 
ARIC (AA) Affymetrix 6.0 Birdseed >95% >90% <1% <10-5 MACH v1.0.16 HapMap2 669,450 
CHS (EA) Illumina 370CNV GenomeStudio >95% >97% NA <10-5 BIMBAM 0.99 HapMap2 306,655 
CHS (AA) 
Illumina 370CNV GenomeStudio >95% >97% NA <10-5 BEAGLE 3.2.1 
HapMap3 
(YRI,ASW,CEU) 
940,567 
Health ABC (EA) Illumina 1M BeadStudio >97% >97% <1% <10-6 MACH v1.0.16 HapMap2 914,263 
Health ABC (AA) 
Illumina 1M BeadStudio >97% >97% <1% <10-6 MACH v1.0.16 
HapMap2 
(YRI,CEU) 
1,007,948 
HCHS/SOL Illumina Omni 2.5M + 
Custom 
GenomeStudio >98% >98% NA <10-5 IMPUTE2 1000G Phase 3 2,294,032 
JHS 
Affymetrix 6.0 Birdseed >95% >95% NA NA IMPUTE v2.1.0 
HapMap2 
(CEU,YRI) 
868,969 
MESA (EA) Affymetrix 6.0 Birdseed >95% >95% <1% <10-4 IMPUTE v2.1.0 HapMap2 730,000 
MESA (AA) Affymetrix 6.0 Birdseed >95% >95% <1% <10-4 IMPUTE v2.1.0 HapMap2 790,581 
MESA (HA) Affymetrix 6.0 Birdseed >95% >95% <1% <10-4 IMPUTE v2.1.0 HapMap2 743,004 
NEO Illumina CoreExome-24v1 GenCall >98% >98% NA <10-5 IMPUTE v2 1000G Phase 1v3 361,046 
PROSPER Illumina 660K BeadStudio >90% >97.5% NA <10-6 MACH v1.0.15 HapMap2 557,192 
Rotterdam 1 Illumina 550K-Duo BeadStudio >98% >98% <1% <10-6 MACH v1.0.15 HapMap2 512,349 
Rotterdam 2 Illumina 550K-Duo, 
610K-Quad 
GenomeStudio >98% >95% <1% <10-6 MACH v1.0.16 HapMap2 537,405 
WHI GARNET Illumina HumanOmni1-Quad BeadStudio NA >98% NA <10-4 BEAGLE v3.3.1 1000G Phase 1v3 NA 
WHI MOPMAP Affymetrix Genome-Wide 
Human CEU 1 
Birdseed NA >90% <0.5% <10-6 MaCH minimac Hapmap 2 NA 
WHI SHARe (AA) 
Affymetrix 6.0 Birdseed NA >95% <1% <10-6 MaCH v1.0.16 
Hapmap 2 
(CEU,YRI) 
NA 
WHI SHARe (HA) Affymetrix 6.0 Birdseed NA >95% <1% <10-6 MaCH v1.0.16 1000G Phase 1v3 NA 
WHIMS Illumina OmniExpress 8.1 Birdseed NA >98% <1% <10-4 MaCH minimac Hapmap 2 NA 
 
EA = European ancestry, AA = African American, HA = Hispanic/Latino ancestry, MAF = minor allele frequency. Study abbreviations: AGES = 
Age, Gene/Environment Susceptibility – Reykjavik Study, ARIC = Atherosclerosis Risk in Communities Study, CHS = Cardiovascular Health 
Study, Health ABC = Health, Aging, and Body Composition Study, HCHS/SOL = Hispanic Community Health Study/Study of Latinos, JHS = 
Jackson Heart Study, MESA = Multi-Ethnic Study of Atherosclerosis, NEO = Netherlands Epidemiology of Obesity, PROSPER = Prospective 
Study of Pravastatin in the Elderly at Risk, Rotterdam 1 = first cohort of the Rotterdam Study, Rotterdam 2 = second cohort of the Rotterdam 
Page 11 
study, WHI GARNET = Women’s Health Initiative Genome-wide Association Research Network into Effects of Treatment, WHI MOPMAP = 
Women’s Health Initiative Modification of Particulate Matter-Mediated Arrhythmogenesis in Populations, WHI SHARe = Women’s Health Initiative 
SNP Health Association Resource, WHIMS = Women’s Health Initiative Memory Study. 
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Supplemental Table 4. Analysis methods for each cohort 
 
Cohort 
Statistical Analysis 
Method Analysis Software 
AGES GEE R bosswithdf 
ARIC GEE R bosswithdf 
CHS GEE R bosswithdf 
Health ABC GEE R bosswithdf 
HCHS/SOL Mixed model R 
JHS GEE R bosswithdf 
MESA GEE R bosswithdf 
NEO Linear regression Probabel v0.4.3 
PROSPER Linear regression Probabel v0.4.3 
Rotterdam 1 GEE R bosswithdf 
Rotterdam 2 GEE R bosswithdf 
WHI GARNET GEE R bosswithdf 
WHI MOPMAP GEE R bosswithdf 
WHI SHARe GEE R bosswithdf 
WHIMS GEE R bosswithdf 
 
Study abbreviations: AGES = Age, Gene/Environment Susceptibility – Reykjavik Study, ARIC = Atherosclerosis Risk in Communities Study, CHS 
= Cardiovascular Health Study, Health ABC = Health, Aging, and Body Composition Study, HCHS/SOL = Hispanic Community Health Study/Study 
of Latinos, JHS = Jackson Heart Study, MESA = Multi-Ethnic Study of Atherosclerosis, NEO = Netherlands Epidemiology of Obesity, PROSPER = 
Prospective Study of Pravastatin in the Elderly at Risk, Rotterdam 1 = first cohort of the Rotterdam Study, Rotterdam 2 = second cohort of the 
Rotterdam study, WHI GARNET = Women’s Health Initiative Genome-wide Association Research Network into Effects of Treatment, WHI 
MOPMAP = Women’s Health Initiative Modification of Particulate Matter-Mediated Arrhythmogenesis in Populations, WHI SHARe = Women’s 
Health Initiative SNP Health Association Resource, WHIMS = Women’s Health Initiative Memory Study. 
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Supplemental Table 5. Genomic inflation factors 
 
 Genomic inflation factors (λ) 
Cohort QT interval JT interval QRS interval 
European Ancestry    
AGES 1.04 1.01 1.05 
ARIC 1.05 1.04 1.03 
CHS 1.04 1.03 1.03 
Health ABC 1.11 1.10 1.07 
MESA 1.05 1.08 1.08 
NEO 1.06 1.08 1.06 
PROSPER 1.02 1.02 1.02 
Rotterdam 1 1.04 1.02 1.04 
Rotterdam 2 1.06 1.07 1.06 
WHI GARNET 1.01 1.03 1.02 
WHI MOPMAP 1.13 1.13 1.13 
WHI WHIMS 1.04 1.05 1.05 
All European 1.01 1.00 1.02 
    
African American    
ARIC 1.05 1.01 1.03 
CHS 1.05 1.06 1.06 
Health ABC 1.07 1.08 1.04 
JHS 1.04 1.04 1.01 
MESA 1.04 1.05 1.06 
WHI SHARe 1.03 1.02 1.01 
All African American 1.00 1.01 1.04 
    
Hispanic/Latino     
HCHS/SOL 1.13 1.12 0.99 
MESA 1.05 1.05 1.03 
WHI SHARe 1.09 1.06 1.02 
All Hispanic 0.97 0.99 0.98 
 
Study abbreviations: AGES = Age, Gene/Environment Susceptibility – Reykjavik Study, ARIC = Atherosclerosis Risk in Communities Study, CHS 
= Cardiovascular Health Study, Health ABC = Health, Aging, and Body Composition Study, HCHS/SOL = Hispanic Community Health Study/Study 
of Latinos, JHS = Jackson Heart Study, MESA = Multi-Ethnic Study of Atherosclerosis, NEO = Netherlands Epidemiology of Obesity, PROSPER = 
Prospective Study of Pravastatin in the Elderly at Risk, Rotterdam 1 = first cohort of the Rotterdam Study, Rotterdam 2 = second cohort of the 
Rotterdam study, WHI GARNET = Women’s Health Initiative Genome-wide Association Research Network into Effects of Treatment, WHI 
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MOPMAP = Women’s Health Initiative Modification of Particulate Matter-Mediated Arrhythmogenesis in Populations, WHI SHARe = Women’s 
Health Initiative SNP Health Association Resource, WHIMS = Women’s Health Initiative Memory Study. 
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Supplemental Table 6. Summary of suggestive sulfonylurea-SNP interaction associations with QT, JT, and QRS intervals from 
ancestry-specific GWAS meta-analyses, P < 10-6 
 
Lead SNP 
Chr:position 
(hg19) Nearest gene Studies 
Min/alt 
alleles MAF Effect SE P Function Coding eQTL (P < 5x10-8) 
            
QT - ALL            
rs1439840 2:123408943  11 C/T 0.07 -4.7 1.0 6.90E-07 Intergenic   
rs17081313 4:32376727  2 T/C 0.03 11.2 2.1 1.69E-07 Intergenic   
            
QT - EA            
rs1890262 1:62114402 TM2D1, NFIA 2 A/G 0.03 13.8 2.8 7.97E-07 Intergenic   
rs6718130 2:18632585 NT5C1B, KCNS3 4 C/A 0.02 9.1 1.7 8.25E-08 Intergenic   
rs6035275 20:19272210 SLC24A3 2 C/T 0.02 -12.0 2.2 1.03E-07 Intronic   
            
QT - AA            
rs12132562 1:172353471 DNM3 6 T/C 0.05 8.5 1.7 3.60E-07 Intronic   
rs1606812 2:147715326 PABPC1P2 3 C/T 0.05 -11.5 2.2 2.60E-07 Intergenic   
rs1106399 2:201003837 SPATS2L, TYW5 3 C/A 0.04 10.5 2.0 2.72E-07 Intergenic  SPATS2L19, 
rs7726558 5:118912598 HSD17B4, FAM170A 5 C/G 0.09 -6.2 1.2 4.39E-07 Intergenic  FAM170A20, 21, HSD17B422 
            
QT - HA            
rs17639063 3:62534435 CADPS 2 G/T 0.04 9.7 1.9 2.84E-07 Intronic   
            
JT - ALL            
rs9853921 3:117959502 LOC105374060 21 C/T 0.33 -2.3 0.5 8.41E-07 Intergenic   
rs624896 5:113856054 KCNN2 7 A/G 0.07 -6.0 1.2 9.05E-07 Intergenic   
rs200214 6:5478793 FARS2 15 G/A 0.02 -3.6 0.7 3.63E-07 Intronic   
rs17156495 7:108763669 THAP5, PNPLA8 5 G/A 0.08 -8.5 1.7 5.30E-07 Intergenic   
            
JT - EA            
rs16895033 8:122297441 HAS2, SNTB1 3 A/G 0.03 -7.9 1.6 9.97E-07 Intergenic   
            
JT - AA            
rs1388107 5:118909006 HSD17B4, FAM170A 6 T/G 0.08 -6.2 1.2 5.34E-07 Intergenic   
rs2182486 13:36367082 MIR548F5 4 C/T 0.07 -13.3 2.5 1.03E-07 Intronic   
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JT - HA            
rs17211409 11:86325887 ME3 2 G/A 0.04 -11.6 2.1 6.02E-08 Intronic  ME322, 23 
rs17107548 14:78892142 NRXN3 3 T/C 0.15 6.6 1.3 9.87E-07 Intronic   
            
QRS - TRANS            
rs2134953 8:4185553 CSMD1 2 G/A 0.04 -7.8 1.4 7.84E-08 Intronic   
rs7861565 9:17346855 CNTLN 5 T/A 0.07 -3.7 0.7 2.14E-07 Intronic   
rs3736352 9:54254589 TINAG 13 C/A 0.06 2.7 0.5 3.44E-07 Missense   
rs10507540 13:46841552 LRRC63 13 G/C 0.14 -2.2 0.4 5.86E-08 Intronic Missense  
rs1397988 18:42022802 SETBP1 18 T/G 0.12 -1.6 0.3 7.15E-07 Intergenic   
rs6088791 20:33907909 UQCC 17 C/T 0.47 -1.1 0.2 7.71E-07 Intronic Missense CEP25022, 23, CPNE119, 23, 
EDEM222, EIF622, ITGB4BP19, 
PROCR19, UQCC21, 23-27 
            
QRS - EA            
rs4591595 4:84124440 PLAC8, COQ2 9 T/C 0.09 -2.8 0.6 3.49E-07 Intergenic   
rs4362469 18:70936558 LOC400655 5 A/C 0.04 -4.8 1.0 6.52E-07 Intergenic   
rs4911179 20:33972899 UQCC 12 A/C 0.39 -1.7 0.3 7.50E-08 Intronic Missense CEP25022, 23, CPNE119, 23, 
EDEM222, EIF622, ITGB4BP19, 
PROCR19, UQCC21, 23-27 
QRS - AA            
rs7861565 9:17346855 CNTLN 4 T/A 0.07 -4.0 0.7 6.25E-08 Intronic   
rs1997103 7:55395390 LANCL2, ELDR 2 C/G 0.05 -9.0 1.7 6.40E-08 Intergenic   
rs12430683 13:99427730 DOCK9, SLC15A1 6 A/G 0.15 -3.2 0.6 1.63E-07 Intergenic   
rs10767455 11:25800278  6 T/A 0.37 2.1 0.4 4.26E-07 Intergenic   
rs10484885 6:90395016 MDN1 2 C/T 0.05 3.5 0.7 9.12E-07 Intronic  ANKRD623, RRAGD23 
rs985292 11:127677874  6 G/A 0.33 2.4 0.5 9.90E-07 Intergenic   
rs4855537 3:68955484 FAM19A4 4 C/A 0.10 -4.6 0.9 9.94E-07 Intronic   
            
QRS - HA            
rs1777084 14:43178407  2 A/G 0.34 -3.3 0.7 9.70E-07 Intergenic   
 
EA = European ancestry, AA = African American, HA = Hispanic/Latino ancestry. Studies = number of cohorts contributing to ancestry-specific 
analysis. Coding = lead SNP in linkage disequilibrium (r2 > 0.8) with a protein coding variant. eQTL = transcripts associated with SNPs in linkage 
disequilibrium (r2 > 0.8) with lead SNP.  
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Supplemental Figure 1. Bioinformatic candidate SNP analysis – QT main effects.  Quantile-quantile plot of QT main-effect genome-
wide association results from the QT Interval-International GWAS Consortium.28 The unfiltered GWAS results are shown in black and 
the candidate SNPs, selected to be likely functional based on bioinformatic analysis of ENCODE and eQTL studies, are plotted in 
red. The candidate SNPs are shifted to the left compared with the unfiltered results, indicating enrichment for signal among the 
candidate SNPs. The lower left sub region of the quantile-quantile plot is displayed as the main panel and the full distribution is 
plotted as the inset. 
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Supplemental Figure 2. Bioinformatic candidate SNP analysis – sulfonylurea-QT interaction effects.  Quantile-quantile plot of 
sulfonylurea-QT interaction genome-wide association results. The unfiltered GWAS results are shown in black and the candidate 
SNPs, selected to be likely functional based on bioinformatic analysis of ENCODE and eQTL studies, are plotted in red. The 
candidate SNPs overlap with the unfiltered results, indicating a lack of enrichment for signal among the candidate SNPs. 
 
   
Page 19 
REFERENCES CITED 
 
1. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, et al. 
Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied 
phenomics. American journal of epidemiology 2007; 165(9): 1076-1087. 
 
2. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design 
and objectives American journal of epidemiology 1989; 129(4): 687-702. 
 
3. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The 
cardiovascular health study: Design and rationale. Annals of epidemiology 1991; 1(3): 
263-276. 
 
4. Sorlie PD, Aviles-Santa LM, Wassertheil-Smoller S, Kaplan RC, Daviglus ML, Giachello 
AL, et al. Design and implementation of the Hispanic Community Health Study/Study of 
Latinos. Annals of epidemiology 2010; 20(8): 629-641. 
 
5. Taylor HA, Jr., Wilson JG, Jones DW, Sarpong DF, Srinivasan A, Garrison RJ, et al. 
Toward resolution of cardiovascular health disparities in African Americans: design and 
methods of the Jackson Heart Study. Ethnicity & disease 2005; 15(4 Suppl 6): S6-4-17. 
 
6. Akylbekova EL, Crow RS, Johnson WD, Buxbaum SG, Njemanze S, Fox E, et al. 
Clinical correlates and heritability of QT interval duration in blacks: the Jackson Heart 
Study. Circulation Arrhythmia and electrophysiology 2009; 2(4): 427-432. 
 
7. Carpenter MA, Crow R, Steffes M, Rock W, Heilbraun J, Evans G, et al. Laboratory, 
reading center, and coordinating center data management methods in the Jackson Heart 
Study. The American journal of the medical sciences 2004; 328(3): 131-144. 
 
8. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-
ethnic study of atherosclerosis: objectives and design. American journal of epidemiology 
2002; 156(9): 871-881. 
 
9. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. 
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised 
controlled trial. Lancet 2002; 360(9346): 1623-1630. 
 
10. Trompet S, de Craen AJ, Postmus I, Ford I, Sattar N, Caslake M, et al. Replication of 
LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic 
analyses. BMC medical genetics 2011; 12: 131. 
 
11. Hofman A, Brusselle GG, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A, 
et al. The Rotterdam Study: 2016 objectives and design update. European journal of 
epidemiology 2015; 30(8): 661-708. 
 
12. Design of the Women’s Health Initiative Clinical Trial and Observational Study. 
Controlled Clinical Trials 1998; 19(1): 61-109. 
 
13. Genomics and Randomized Trials Network (GARNET). US Department of Heath & 
Human Services: National Institutes of Health National Genome Institute 
http://wwwgenomegov/27541119  Accessed January 28, 2016. 
Page 20 
 
14. Modification of PM-Mediated Arrhythmogenesis in Populations. US  Department of 
Health & Human Services: National Institutes of Health  Research portfolio online 
reporting tools 
http://projectreporternihgov/project_info_descriptioncfm?aid=7984809&icde=19283008 
Accessed January 28 2016. 
 
15. Shumaker SA, Reboussin BA, Espeland MA, Rapp SR, McBee WL, Dailey M, et al. The 
Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen 
therapy in preventing and slowing the progression of dementia. Control Clin Trials 1998; 
19(6): 604-621. 
 
16. SNP Health Association Resource Project. US  Department of Health & Human 
Services: National Institutes of Health  National Heart, Lung and Blood Institute 
https://wwwnhlbinihgov/resources/geneticsgenomics/programs/sharehtm Accessed 
January 28 2016. 
 
17. Willems JL, Arnaud P, van Bemmel JH, Bourdillon PJ, Degani R, Denis B, et al. A 
reference data base for multilead electrocardiographic computer measurement 
programs. J Am Coll Cardiol 1987; 10(6): 1313-1321. 
 
18. van Bemmel JH, Kors JA, van Herpen G. Methodology of the modular ECG analysis 
system MEANS. Methods Inf Med 1990; 29(4): 346-353. 
 
19. Fairfax BP, Humburg P, Makino S, Naranbhai V, Wong D, Lau E, et al. Innate immune 
activity conditions the effect of regulatory variants upon monocyte gene expression. 
Science 2014; 343(6175): 1246949. 
 
20. Li Q, Stram A, Chen C, Kar S, Gayther S, Pharoah P, et al. Expression QTL-based 
analyses reveal candidate causal genes and loci across five tumor types. Hum Mol 
Genet 2014; 23(19): 5294-5302. 
 
21. Greenawalt DM, Dobrin R, Chudin E, Hatoum IJ, Suver C, Beaulaurier J, et al. A survey 
of the genetics of stomach, liver, and adipose gene expression from a morbidly obese 
cohort. Genome Res 2011; 21(7): 1008-1016. 
 
22. Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. 
Systematic identification of trans eQTLs as putative drivers of known disease 
associations. Nat Genet 2013; 45(10): 1238-1243. 
 
23. Kirsten H, Al-Hasani H, Holdt L, Gross A, Beutner F, Krohn K, et al. Dissecting the 
genetics of the human transcriptome identifies novel trait-related trans-eQTLs and 
corroborates the regulatory relevance of non-protein coding locidagger. Hum Mol Genet 
2015; 24(16): 4746-4763. 
 
24. Battle A, Mostafavi S, Zhu X, Potash JB, Weissman MM, McCormick C, et al. 
Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 
922 individuals. Genome Res 2014; 24(1): 14-24. 
 
25. Larson NB, McDonnell S, French AJ, Fogarty Z, Cheville J, Middha S, et al. 
Comprehensively evaluating cis-regulatory variation in the human prostate transcriptome 
Page 21 
by using gene-level allele-specific expression. American journal of human genetics 
2015; 96(6): 869-882. 
 
26. Zeller T, Wild P, Szymczak S, Rotival M, Schillert A, Castagne R, et al. Genetics and 
beyond--the transcriptome of human monocytes and disease susceptibility. PLoS One 
2010; 5(5): e10693. 
 
27. Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, et al. Integrated 
systems approach identifies genetic nodes and networks in late-onset Alzheimer's 
disease. Cell 2013; 153(3): 707-720. 
 
28. Arking DE, Pulit SL, Crotti L, van der Harst P, Munroe PB, Koopmann TT, et al. Genetic 
association study of QT interval highlights role for calcium signaling pathways in 
myocardial repolarization. Nat Genet 2014; 46(8): 826-836. 
 
 
 
